Abstract Aims-To investigate the effect of combination endocrine treatment (CET) or luteinising hormone releasing hormone agonist and flutamide on non-neoplastic prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. Methods-The morphology, including the mitotic activity, of 12 radical prostatectomies from patients with prostatic adenocarcinoma pretreated for three months with CET was evaluated in haematoxylin and eosin stained sections and compared with an untreated age and stage matched control group. Results-A differential effect on the nonneoplastic prostate was observed. In fact, the transition zone of the treated prostate showed simplification of the glandular lobules: the ducts and acini were small without undulations of the epithelial border and with a prominent basal cell layer. Within the peripheral zone there was inconspicuous branching of the ducts and acini which looked dilatated and lined by flattened atrophic epithelium. Prostatic intraepithelial neoplasia occurred in scattered ducts and acini in the peripheral zone of 10 of the 12 patients. The epithelial cell lining showed a prominent basal cell layer. A certain degree of secretory cell type stratification was always present. However, crowding was less evident than in the untreated prostate because of cytoplasmic clearing and enlargement as a result of coalescence of vacuoles. The treated adenocarcinomas had neoplastic acini which looked small and shrunken, and areas of individual infiltrating tumour cells separated by abundant interglandular connective tissue. The secretory cells of the nonneoplastic, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma lesions had inconspicuous nucleoli, nuclear shrinkage, chromatin condensation, and cytoplasmic clearing. Apoptotic bodies were easily identifiable in all the cell layers. The lumina were rich in macrophages, sloughed secretory cells with degenerative features, and apoptotic bodies. Mitoses were not observed in any of the treated non-neoplastic prostate, prostatic intraepithelial neoplasia, or prostatic adenocarcinomas, whereas the mitotic frequency increased from nonneoplastic prostate through prostatic intraepithelial neoplasia up to prostatic adenocarcinomas in the untreated specimens.
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Conclusions-CET before radical prostatectomy causes regressive epithelial changes together with enhanced apoptosis and blocked mitotic activity. For many years, testicular androgen deprivation by oestrogen treatment or orchidectomy has been the standard hormonal treatment for advanced invasive adenocarcinoma of the prostate.' Recently, new drugs, especially agonists of luteinising hormone releasing hormone (LHRH) and anti-androgens, such as flutamide, have been introduced.2' Although the efficacy of these new drugs used alone is equivalent to that of standard treatment, their use avoids the major side effects of oestrogen treatment and the psychological impact of orchidectomy.4 Treatment combining an LHRH agonist and a pure antiandrogen drug (combination endocrine treatment or CET) to block simultaneously adrenal and testicular androgen has been shown to be superior to either approach used alone.5-7
Some histological changes induced by CET in human prostate cancer have recently been described.8 "' However, there is scant information on the differential effect of an LHRH agonist and flutamide on the normal prostate zones and, in particular, the influence of CET on prostatic intraepithelial neoplasia.
The aim of our study was to evaluate the effect of CET on non-neoplastic prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinomas in resected prostatectomy specimens with emphasis on morphology and mitotic activity.
Methods
The study included the histopathological material from 12 consecutive patients (age range 60 to 70 years) who had undergone a radical prostatectomy for stage B prostatic adenocarcinoma"2 after temporary CET.
Before surgery the patients had received CET for three months. Radical prostatectomy was performed while the patient was still receiving treatment. histological changes induced by CET with the prostate morphology of untreated specimens. The control group (age matched with the treated group) underwent a radical prostatectomy for stage B prostatic adenocarcinoma without receiving chemotherapy, hormone, or radiation treatment before surgery. We chose to use a separate control group of untreated patients instead of the pretreatment prostate biopsy specimens because the latter type of diagnostic procedure does not usually yield representative material containing prostatic adenocarcinoma, prostatic intraepithelial neoplasia, and non-neoplastic prostate for a thoroughly comparative study, especially for mitosis counts.
The prostatectomy specimens were delivered fresh from the operating room shortly after excision. They were cut into slices about 0 3 cm thick and then fixed for 24-48 hours in neutral buffered formalin (4%), dehydrated in graded alcohols, cleared in xylene, and embedded in paraffin wax. The haematoxylin and eosin stained sections of the radical prostatectomies of the treated group were reviewed by one of us (RM) to select slides containing prostatic adenocarcinoma, prostatic intraepithelial neoplasia (if present), and non-neoplastic tissue. Slides with acute and chronic inflammation were discarded. The slides selected for prostatic adenocarcinoma also covered the peripheral zone of the prostate including the capsule-that is, the advancing front of the carcinoma where the proliferative activity is thought to be higher than in the centre of the tumour nodule.9 Because the prostatic epithelium adjacent to prostatic intraepithelial neoplasia and prostatic adenocarcinoma usually shows a proliferative pattern,'4 the sections selected to represent the non-neoplastic tissue were at a distance from prostatic intraepithelial neoplasia and prostatic adenocarcinoma and covered the peripheral and transition zones. The former comprises about 70% of the mass of the glandular prostate and is adjacent to the rectum. The latter surrounds the urethra from the base of the gland tapering to the verumontanum.
Mitoses were assessed on conventional 3 pm thick histological sections (microtome setting) cut from formalin fixed, paraffin wax embedded material. The research project was conducted using haematoxylin and eosin stained sections. For the analyses of mitotic frequency and location, the sections were evaluated by one of our team using a Leitz Orthoplan microscope equipped with a x 63 objective and an eyepiece graticule.'3 The criteria used to identify the mitotic figures and to distinguish them from apoptotic bodies have been detailed before.'5 In particular, mitoses are characterised by the absence of nuclear membrane, absence of a clear zone at the centre, by the presence of hairy instead of triangular or spiky projections, and basophilia of the surrounding cytoplasm. In contrast, apoptotic bodies are round or oval in shape and variable in size, made up of masses of pyknotic chromatin surrounded by narrow cytoplasmic rims. The percentage of mitoses from a minimum of 1000 nuclei per case (also called the mitotic index) was calculated separately for each cell layer. The time needed to analyse each case was about 60 minutes.
The data were stored in an Apple Macintosh II computer. StatView II software was used for the calculation of the mean and standard error of mean (SEM), as well as for statistical analyses (Kruskal-Wallis and Mann-Whitney U tests). Reproducibility was tested for by duplicate evaluations of mitoses in six untreated cases (two benign prostatic hyperplasia, two prostatic intraepithelial neoplasia, and two prostatic adenocarcinoma), but no significant differences were found.
Results
For the treated group, the following morphological patterns of prostate diseases were present and investigated in the 12 patients: non-neoplastic prostate (p = 12), prostatic intraepithelial neoplasia (n = 10), prostatic adenocarcinoma (seven cases with acinar pattern, four with cribriform pattern, and one with solid or trabecular pattern). For the untreated group, the following morphological patterns of prostrate diseases were investigated in prostatectomy specimens: nonneoplastic prostate (n = 20), prostatic intraepithelial neoplasia of low grade (PINlow) (n = 10), and prostatic intraepithelial neoplasia of high grade (PINhigh) (n = 10), and prostatic adenocarcinoma ( In the non-neoplastic peripheral zone, the main origin site of prostatic intraepithelial neoplasia and prostatic adenocarcinoma, we found diffuse changes which are different from those in the transition zone. This is a poorly recognised finding. To the best of our knowledge, Te'tu et alP°were the only previous authors to mention very briefly that the glands at the periphery of the prostate treated with an LHRH agonist and flutamide were dilatated and lined by atrophied epithelium. We do not have a definitive explanation for these morphological differences between the nonneoplastic prostate zones. Although the differential response might be linked to differences in honmone receptors, we advocate the alternative, traditional explanation for focal atxopy24~--that is, as the consequenceofdca obstruction associated with a CET effect.
Prostatic intraepithelial neoplasia is considered to be a premalignant lesion which might progress to prostatic adenocarcinoma.13 14 Ellison et at8 and Tetu et al'0 mentioned that CET has some kind of effect on prostatic intraepithelial neoplasia lesions. In particular, the former group recently affirmed that the extent of high grade prostatic intraepithelial neoplasia decreased significantly in patients receiving a total androgen blockade. Even though the extent of prostatic intraepithelial neoplasia was evaluated visually, we reached the same conclusion in our study. In fact, prostatic intraepithelial neoplasia lesions were localised in scattered ducts compared with the control group in which the extension was greater. However, to our knowledge, the morphology of the regressing prostatic intraepithelial neoplasia lesions has not been described before. Our study showed regressive changes in the secretory cells, while the mitotic activity was abolished. The nuclei showed chromatin condensation and pyknosis. These changes are probably associated with qualitative and quantitative DNA alterations and might possibly be linked to apoptosis. A reduced DNA content was observed by Peters and Walsh20 in non-neoplastic prostate. In their experience androgen deprivation for six months induced a 40% decrease in nuclear DNA content. This has also been our experience with flow cytometric analysis: in fact, DNA histograms with a hypodiploid mode were obtained from some of the fresh prostate specimens (unpublished data). The cytoplasmic changes are of the regressive type, in agreement with the study by Tetu et al,'0 which showed that prostatic specific antigen immunostaining was weaker and the number of positive cells substantially reduced in prostatic adenocarcinoma treated by CET.
Apoptotic bodies were more frequently seen in the regressing prostatic intraepithelial neoplasia lesions than in the untreated lesions and were observed at the level of the cell layers as well as in the lumina. This was observed after CET in the normal and neoplastic prostate in studies in which it was suggested that CET induced a certain degree of epithelial regression by enhancing the cell death phenomenon called apoptosis.2526 The findings of the present investigation with the experimental study of Szende et al 27 who investigated the effects of LHRH agonists and somatostatin on cancer in hamsters. They observed that the tumours treated with agonists showed regressive histological changes characteristic of apoptosis. Our observation probably corresponds to the finding of "progressive nuclear pyknosis" observed by Helpap28 in patients receiving hormone treatment (the type of treatment was not specified). Apoptosis was evaluated by Stiens et al 29 in patients with prostatic carcinoma before and after oestrogen and radiation treatment. They observed that the apoptosis index can increase 10-fold within the first 10 days of treatment; under radiation treatment, apoptotic bodies can also be measured as increasing. Histologically, apoptotic bodies were seen in the intercellular space and in the lumen where some of the bodies appeared in the macrophage cytoplasm. This apoptotic body location supports the conclusions made by Kerr et al 30 The morphological changes do not seem to be equally distributed over the prostatic adenocarcinoma lesions. Such unequal distribution seems to be linked to the tumour pattern.
Those adenocarcinomas with an acinar pattern were greatly affected by CET: in fact, the architectural and cell damage is obvious and easily recognisable. CET exerted a pronounced effect, to the point that the tumour acini shrunk, making it difficult to say whether they belonged to the large or small acinar pattern categories. In the cribriform and solid or trabecular pattern the changes were not so pronounced as in the acinar pattern, and some nuclear details were still recognisable, a feature also present in some ducts and acini with prostatic intraepithelial neoplasia. This means that the high grade lesions, whether infiltrating or intraductal, might give a poorer response to three months of CET, and that when high grade lesions are observed in a pretreatment biopsy specimen, a longer period of CET has to be planned. Alternatively, as postulated by Akakura et al,40 androgen suppression could be of the intermittent type. These authors studied the effects of intermittent androgen suppression on androgen dependent tumours and suggested that the replacement of androgens after a certain period of androgen suppression might result in the regeneration and differentiation of stem cells with further apoptotic potential. These cells could then be eliminated by successive androgen withdrawal.
In conclusion, CET induces regressive changes in the secretory cells and blocks the mitotic activity of the non-neoplastic prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. In particular, its effect on prostatic intraepithelial neoplasia may be of paramount importance for the pharmacological treatment of prostate glands with a biopsy diagnosis of prostatic intraepithelial neoplasia without morphological or clinical evidence of prostatic adenocarcinoma. Further studies are necessary to investigate the longer term effect of CET and the importance of basal cell preservation in the regrowth of lesions when CET is discontinued. 
